AIM: To assess the prevalence of DSM-III-R axes I and II disorders and the severity of psychiatric symptoms in cannabis users who did not use other illicit drugs. DESIGN: Cross-sectional psychiatric examination of subjects with different patterns of cannabis use: cannabis dependence, abuse and occasional use. PARTICIPANTS: One hundred and thirty-three cannabis users identified through random urine testing of draftees to the Italian army and interviewed after 2-5 days of abstinence from drug use. MEASUREMENTS: The subjects completed the Beck Depression Inventory, the Spielberger State-Trait Anxiety Index and the 20-item revised Toronto Alexithymia Scale and were then interviewed with the Structured Clinical Interview for DSM-III-R. FINDINGS: The prevalence of co-morbid psychiatric disorders varied with the pattern of cannabis use: 83% of subjects with DSM-III-R cannabis dependence, 46% of those with DSM-III-R cannabis abuse and 29% of occasional users received at least one DSM-III-R psychiatric diagnosis. The severity of depressive, anxious and alexithymic symptoms increased progressively with the degree of involvement with cannabis. CONCLUSIONS: In this sample of young men, the risk of associated psychiatric disabilities varied with the pattern of cannabis use. Chronic use of cannabis was associated with a high prevalence of co-morbid psychiatric disorders.
AIM: To assess the prevalence of DSM-III-R axes I and II disorders and the severity of psychiatric symptoms in cannabis users who did not use other illicit drugs. DESIGN: Cross-sectional psychiatric examination of subjects with different patterns of cannabis use: cannabis dependence, abuse and occasional use. PARTICIPANTS: One hundred and thirty-three cannabis users identified through random urine testing of draftees to the Italian army and interviewed after 2-5 days of abstinence from drug use. MEASUREMENTS: The subjects completed the Beck Depression Inventory, the Spielberger State-Trait Anxiety Index and the 20-item revised Toronto Alexithymia Scale and were then interviewed with the Structured Clinical Interview for DSM-III-R. FINDINGS: The prevalence of co-morbid psychiatric disorders varied with the pattern of cannabis use: 83% of subjects with DSM-III-R cannabis dependence, 46% of those with DSM-III-R cannabis abuse and 29% of occasional users received at least one DSM-III-R psychiatric diagnosis. The severity of depressive, anxious and alexithymic symptoms increased progressively with the degree of involvement with cannabis. CONCLUSIONS: In this sample of young men, the risk of associated psychiatric disabilities varied with the pattern of cannabis use. Chronic use of cannabis was associated with a high prevalence of co-morbid psychiatric disorders.
Authors: M E Page; V C Oropeza; S E Sparks; Y Qian; A S Menko; E J Van Bockstaele Journal: Pharmacol Biochem Behav Date: 2007-01-09 Impact factor: 3.533
Authors: Lauren Micalizzi; Leslie A Brick; Sarah A Thomas; Jennifer Wolff; Christianne Esposito-Smythers; Anthony Spirito Journal: Subst Use Misuse Date: 2020-02-28 Impact factor: 2.164
Authors: Michael J Zvolensky; Peter Lewinsohn; Amit Bernstein; Norman B Schmidt; Julia D Buckner; John Seeley; Marcel O Bonn-Miller Journal: J Psychiatr Res Date: 2008-02-20 Impact factor: 4.791